JO
GALT icon

John Overdeck’s Galectin Therapeutics GALT Stock Holding History

John Overdeck’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.48M Sell
318,245
-148,818
-32% -$386K ﹤0.01% 3285
2026
Q1 		$1.3M Buy
467,063
+450,451
+2,712% +$1.37M ﹤0.01% 3059
2025
Q4 		$69.1K Sell
16,612
-35
-0.2% -$184 ﹤0.01% 3894
2025
Q3 		$70.5K Buy
+16,647
New +$62.6K ﹤0.01% 3509
2021
Q1 		– Sell
-60,181
Closed -$135K – 3964
2020
Q4 		$135K Sell
60,181
-61,403
-51% -$161K ﹤0.01% 3179
2020
Q3 		$325K Buy
121,584
+45,394
+60% +$127K ﹤0.01% 2538
2020
Q2 		$233K Buy
76,190
+59,258
+350% +$149K ﹤0.01% 2539
2020
Q1 		$33K Buy
+16,932
New +$41.2K ﹤0.01% 2953

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

John Overdeck's GALT Position: Q2 2026 in Review

John Overdeck reduced its Galectin Therapeutics (GALT) stake by 32% in Q2 2026, selling an estimated $386K and leaving 318,245 shares worth $1.48M. The position accounts for ﹤0.01% of the portfolio, ranked #3285.

John Overdeck first reported a position in GALT in Q1 2020 and has held it in 8 quarters since. 97 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • John Overdeck held 318,245 shares of Galectin Therapeutics worth $1.48M as of Q2 2026.
  • John Overdeck sold 148,818 Galectin Therapeutics shares in Q2 2026, an estimated $386K.
  • Galectin Therapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #3285 holding.
  • John Overdeck first reported a position in Galectin Therapeutics in Q1 2020 and has held it in 8 quarters since.
  • 97 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.